Beyond acquisitions, we continue to expect steady future dividends, supported by a payout ratio of close to 50% relative to adjusted earnings per share. Patents, economies of scale, and a powerful ...

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term ...

An FDA expert panel on Thursday voted against a broader use of Merck (MRK) and Bristol-Myers (BMY) immune checkpoint inhibitors Keytruda and Opdivo. Read more here.

The days of broad stomach cancer labels for PD-1 inhibitors appear to be numbered.  | The days of broad stomach cancer labels ...

Merck MRK announced data from the phase III KEYFORM-007 study, which evaluated a fixed-dose combination of its anti-LAG-3 ...

During clinical trials, Bristol Myers Squibb's KarXT was said to offer better treatment with fewer side effects. Meanwhile, Pfizer's sickle cell disease treatment Oxbryta was withdrawn from all ...

Merck & Co. has picked up options on two Evaxion vaccine candidates, paying $3.2 million and dangling more than $1 billion in ...

Bob Duggan, 80, has gone from baking cookies to building robots, investing in biotech companies, and ranking among the ...

We recently compiled a list of the 7 Undervalued Blue Chip Stocks To Buy Right Now. In this article, we are going to take a ...

Here are seven undervalued stocks to buy, according to CFRA, with forward earnings multiples of less than 15: *As of Sept. 25 ...

The ODAC will weigh risk-benefit analyses from the FDA and sponsors on Keytruda, Opdivo, and Tevimbra when given with chemo in all comers and in PD-L1-positive subgroups.

Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of ...